萬泰生物(603392.SH)股價近期漲幅較大提示風險:目前僅有戊肝疫苗、雙價宮頸癌疫苗(HPV2價)兩個產品
格隆匯5月21日丨萬泰生物(603392.SH)發佈股票交易異常波動及風險提示公告,公司股票價格近期漲幅較大,自2020年4月29日至5月21日,已連續13個交易日(首日除外)漲停。公司特別提醒投資者,注意二級市場交易風險。
公司市盈率水平較高,根據同花順iFinD數據顯示,截至2020年5月21日,公司滾動市盈率為78.96,公司所屬的醫藥製造業的行業滾動市盈率為23.36,公司的滾動市盈率明顯高於行業平均值;公司靜態市盈率為90.37,公司所屬的醫藥製造業的行業靜態市盈率為65.44,公司的靜態市盈率明顯高於行業平均值。請投資者注意交易風險。
公司2019年度淨利潤相比2018年度下滑28.20%,2020年受疫情影響公司淨利潤存在波動的風險。
目前,公司主營業務為體外診斷試劑和疫苗兩大類,其中體外診斷試劑業務2019年佔總體收入的98%,疫苗業務在整體收入比重不足2%。
診斷試劑行業屬於充分競爭的行業,市場逐步向龍頭企業集中,行業集中度不斷提高。如果公司不能持續地在市場競爭中保持優勢,將會面臨增長放緩、市場份額下降的風險。
疫苗行業屬技術密集型行業,開發週期長,投資風險大,需要保持持續不斷的研發投入,保持技術領先,如後續公司在研發投入方面不足,將難以保證創新疫苗的領先地位。目前公司僅擁有戊肝疫苗、雙價宮頸癌疫苗(HPV2價)兩個產品,產品品類相對較少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.